Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Grup Recerca Addiccions Clinic (GRAC-GRE) Psychiatry Department, Neurosciences Institute, Hospital Clínic, Universitat de Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Grup Recerca Addiccions Clinic (GRAC-GRE) Psychiatry Department, Neurosciences Institute, Hospital Clínic, Universitat de Barcelona, Spain.
Eur Neuropsychopharmacol. 2020 Apr;33:1-35. doi: 10.1016/j.euroneuro.2020.02.003. Epub 2020 Mar 9.
Cannabis is the third most used psychoactive substance worldwide. The legal status of cannabis is changing in many Western countries, while we have very limited knowledge of the public health impact of cannabis-related harms. There is a need for a summary of the evidence of harms and risks attributed to cannabis use, in order to inform the definition of cannabis risky use. We have conducted a systematic review of systematic reviews, aiming to define cannabis-related harms. We included systematic reviews published until July 2018 from six different databases and following the PRISMA guidelines. To assess study quality we applied the AMSTAR 2 tool. A total of 44 systematic reviews, including 1,053 different studies, were eligible for inclusion. Harm was categorized in three dimensions: mental health, somatic harm and physical injury (including mortality). Evidence shows a clear association between cannabis use and psychosis, affective disorders, anxiety, sleep disorders, cognitive failures, respiratory adverse events, cancer, cardiovascular outcomes, and gastrointestinal disorders. Moreover, cannabis use is a risk factor for motor vehicle collision, suicidal behavior and partner and child violence. Cannabis use is a risk factor for several medical conditions and negative social consequences. There is still little data on the dose-dependency of these effects; evidence that is essential in order to define, from a public health perspective, what can be considered risky use of cannabis. This definition should be based on quantitative and qualitative criteria that informs and permits the evaluation of current approaches to a regulated cannabis market.
大麻是世界上使用第三多的精神活性物质。大麻在许多西方国家的法律地位正在发生变化,而我们对与大麻相关的危害对公共健康的影响知之甚少。需要对归因于大麻使用的危害和风险的证据进行总结,以便为定义大麻的危险使用提供依据。我们对系统评价进行了系统评价,旨在定义与大麻相关的危害。我们纳入了截至 2018 年 7 月来自六个不同数据库的系统评价,并遵循 PRISMA 指南。为了评估研究质量,我们应用了 AMSTAR 2 工具。共有 44 项系统评价,包括 1053 项不同的研究,符合纳入标准。危害分为三个维度:心理健康、躯体伤害和身体伤害(包括死亡率)。有证据表明,大麻使用与精神病、情感障碍、焦虑、睡眠障碍、认知失败、呼吸道不良事件、癌症、心血管结局和胃肠道疾病之间存在明确关联。此外,大麻使用是机动车碰撞、自杀行为以及伴侣和儿童暴力的危险因素。大麻使用是几种医疗状况和负面社会后果的危险因素。对于这些影响的剂量依赖性仍然缺乏数据;为了从公共卫生角度定义什么可以被认为是大麻的危险使用,这些证据是必不可少的。该定义应基于定量和定性标准,为评估当前对受监管大麻市场的方法提供信息和许可。